Tag: Medical

Medtronic plc (NYSE:MDT) Shares Sold by Cetera Advisors LLC

[ad_1]

Cetera Advisors LLC cut its position in Medtronic plc (NYSE:MDT – Get Rating) by 30.5% in the second quarter, Holdings Channel reports. The firm owned 39,489 shares of the medical technology company’s stock after selling 17,306 shares during the period. Cetera Advisors LLC’s holdings in Medtronic were worth $3,544,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in MDT. Vanguard Group Inc. boosted its position in shares of Medtronic by 6.5% in the 1st quarter. Vanguard Group Inc. now owns 120,557,488 shares of the medical technology company’s stock valued at $13,375,853,000 after purchasing an additional 7,403,778 shares during the period. Invesco Ltd. boosted its position in shares of Medtronic by 29.6% in the 1st quarter. Invesco Ltd. now owns 12,205,798 shares of the medical technology company’s stock valued at $1,354,234,000 after purchasing an additional 2,789,882 shares during the period. Bridgewater Associates LP acquired a new stake in shares of Medtronic in the 1st quarter valued at about $208,596,000. Sanders Capital LLC boosted its position in shares of Medtronic by 14.3% in the 1st quarter. Sanders Capital LLC now owns 13,517,677 shares of the medical technology company’s stock valued at $1,660,016,000 after purchasing an additional 1,687,707 shares during the period. Finally, Capital Research Global Investors lifted its position in Medtronic by 6.8% during the 1st quarter. Capital Research Global Investors now owns 22,023,597 shares of the medical technology company’s stock worth $2,443,518,000 after acquiring an additional 1,405,249 shares during the period. 79.81% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Morgan Stanley decreased their price objective on Medtronic from $101.00 to $97.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 11th. Citigroup decreased their price objective on Medtronic from $110.00 to $108.00 in a research report on Wednesday, October 5th. Wells Fargo & Company decreased their price objective on Medtronic from $104.00 to $96.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 24th. Royal Bank of Canada decreased their price objective on Medtronic from $122.00 to $110.00 in a research report on Wednesday, September 7th. Finally, Piper Sandler reduced their price target on Medtronic from $100.00 to $90.00 in a report on Tuesday, August 23rd. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $106.75.

Medtronic Stock Performance

Medtronic stock opened at $82.29 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.23 and a current ratio of 1.58. The stock has a fifty day moving average of $84.04 and a two-hundred day moving average of $90.04. The company has a market capitalization of $109.38 billion, a price-to-earnings ratio of 21.26, a PEG ratio of 2.17 and a beta of 0.77. Medtronic plc has a fifty-two week low of $79.19 and a fifty-two week high of $118.80.

Medtronic (NYSE:MDT – Get Rating) last announced its quarterly earnings data on Tuesday, August 23rd. The medical technology company reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.01. The business had revenue of $7.37 billion during the quarter, compared to the consensus estimate of $7.20 billion. Medtronic had a return on equity of 13.64% and a net margin of 16.75%. During the same quarter in the previous year, the business earned $1.41 earnings per share. On average, analysts anticipate that Medtronic plc will post 5.52 EPS for the current fiscal year.

Insider Activity

In other news, EVP Hoedt Rob Ten sold 2,404 shares of Medtronic stock in a transaction on Friday, October 14th. The stock was sold at an average price of $81.54, for a total value of $196,022.16. Following the completion of the sale, the executive vice president now owns 43,483 shares of the company’s stock, valued at $3,545,603.82. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.29% of the company’s stock.

About Medtronic

(Get Rating)

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

Featured Stories

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Get Rating).

Receive News & Ratings for Medtronic Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Medtronic and related companies with MarketBeat.com’s FREE daily email newsletter.

[ad_2]

ABMN Staff

Source link

November 22, 2022
Austin Pets Alive! | Pancake

[ad_1]

Nov 17, 2022

This is a story about a kitty cat who went on the lamb and is now back in our care, after taunting the staff and volunteers of APA! for over a year! We applaud her efforts, but it is time to get this little lady some medical attention.

When Pancake first arrived at APA!’s main facility, she was clearly pretty scared, making her a flight risk candidate. Fly, she did. Luckily, she stuck around campus, making appearances. For months, the staff and volunteers reported “Pancake sightings.” We even attempted several strategized opportunities to get her back into our hands, with the biggest goal of getting her spayed. We have several “community cats” hanging around our facility – our very own barn cats! We care about this population and want to make sure they receive necessary medical attention so that everyone stays safe and can live a healthy life!

The whole organization has been in on it, for over a year! Here are some highlights from email threads:

“Volunteer just reported seeing them on the roof!”

“I was informed this cat was just spotted under a red car in front of the medical clinic!”

“Operation Ruin Pancake’s Romance”

“After a week long battle….. Pancake wins.”

“Catching Pancake (the Remix)”

The teams have finally found success and are celebrating that this girl officially received her spay surgery and has been released back into the family she created with the other APA! Community Cats. We have the honor of Pancake making her appearances around campus for many years to come!

Our barn cat program supports the cats who prefer the wild frontier. While traditionally seen as “unadoptable” in the sheltering world, our barn cat program has created a way for everyone to live in harmony– community cats get to go about their feral cat lives and those that adopt them receive pest control services for the simple cost of room and board.

Think you need a barn cat or two to support some property you have? Reach out to us – we can fill the order for you!

[ad_2]

Source link

November 16, 2022
FDA Announces Adderall Shortage

[ad_1]

The FDA has confirmed a nationwide shortage of the attention-deficit/hyperactivity disorder medication Adderall due to manufacturing issues, with the shortage expected to last through the end of the year. What do you think?

“Pretty sure meth’s still in stock.”

Miles Seelbach, Crypto Banker

“Between this and the formula shortage, what am I supposed to feed my baby?”

Anita Santana, Cannoneer

“I guess I have to go back to bribing teachers.”

Hank Schilsky, Content Aggregator

[ad_2]

Source link

October 17, 2022
Herschel Walker Gets Line Of Lecterns To Block For Him During Debate

[ad_1]

Read more…

[ad_2]

Source link

October 14, 2022
Austin Pets Alive! | A letter from Dr. Jefferson on Zydeco

[ad_1]

Mar 31, 2021

As you likely know, Austin Pets Alive!’s daily work centers around our mission to end the unnecessary killing of shelter pets, which sounds generic but in reality, is extremely difficult. It means that we purposely take pets in who are either already scheduled or soon to be scheduled to be euthanized. There’s no easy way to categorize these populations of animals as they vary. They can be like the animals we save in deep South Texas, healthy adorable pets with no space to go to like we saw during the ice storm, or the animals who have been chosen for a reason to be killed or eliminated from the population.

It’s the latter group that I’ll speak about here. We realized that the most measurable way to make an impact in ending the killing of shelter pets was to actually intervene at the last second before the animal was facing euthanasia, rather than pull animals into our program who were at the front end of their stay in a shelter. The reason that is important is that many rescue groups have the resources to help animals who are ready for adoption and we found a huge gap in the number of groups who can help the animals at the end of the line, especially en masse in large shelters.

We built our programs around these animals – puppies with parvovirus, bottle babies, cats with ringworm, those with Feline Leukemia, etc. Over time we have been able to expand the limits, beyond the city of Austin, of where we intervene in the deaths of these medical groups of animals. However, for big dogs with significant behavior challenges, it is much harder. We have only been able to intervene in the deaths of the behavior dogs in the city of Austin, Austin Animal Center, because of the expense, time, and difficulty in finding solutions for these dogs.

Just like with medical cases, we know we will lose some but we take them anyway and we try.

If you’d like to read more about Zydeco and the difficult situation we are in, please take time to hear from one of his closest friends and one who’s worked with him the longest, Hana Garner our Dog Behavior Training Manager. Her letter tells his story from start to finish and will offer insight into why we’ve made the decision we have.

[ad_2]

Source link

March 31, 2021
Launch of Migraine Cannabis Study Planned With Patient Support Group MigraineBuds, Chronic Pain Specialist Dr. Sana-Ara Ahmed and the Canadian Institute for Medical Advancement

[ad_1]

Patient support group takes matters into their own hands, and seeks out help to conduct a Migraine Cannabis Study

Press Release
–

updated: Nov 10, 2017

TORONTO, November 10, 2017 (Newswire.com)
–
MigraineBuds is an organization started by a patient advocate Jodie Epstein who suffers from chronic migraines. This online support group has information on cannabis specific to migraines and headaches. The MigraineBuds community is 1750 patients strong and growing, which provides a forum for discussing everything cannabis- and migraine-related. Jodie was eager to create a safe, non-judgmental space to have these conversations.

Migraine affects approximately 10 percent of people worldwide, with many patients unable to find adequate pain management. Many migraineurs also suffer from Medication Overuse Headache (MOH). MOH occurs when pain relief medications are taken too frequently. This can occur when a patient has taken too much caffeine, ergots, or pharmaceutical medications such as opioids, triptans or non-steroidal anti-inflammatory drugs.

“The social reform of chronic pain medicine includes medical cannabis as a viable and first choice option for migraine sufferers. Review of medical history indicates that the Cannabis sativa plant was frequently used by physicians to treat acute and chronic migraine headaches in North America and was discontinued when drug prohibition removed the plant from the pharmacopeia. I have been treating chronic migraine sufferers with medical cannabis with great results and look forward to the research benefits for all of society.”

– Dr. Sana-Ara Ahmed, M.D., FRCPC Anesthesiologist & Chronic Pain Specialist

What we are looking to study and why

The MigraineBuds community is interested and keen to participate in clinical research that will help to demonstrate the efficacy of cannabis in the treatment of migraine. The proposed study will also examine the effect cannabis may have on MOH.

The Canadian Institute for Medical Advancement, a research organization, has agreed to help conduct the study. Accordingly, Dr. Sana-Ara Ahmed, a clinical Anesthesiologist & Chronic Pain Specialist, has agreed to participate in the research study. Dr. Ahmed is an advocate for chronic migraine pain patients and treats numerous patients at her clinic The Health Boutique™. Dr. Ahmed is a specialist and educator in the use of medical cannabis for chronic pain, including migraines, and advocates the use of cannabis as an effective method of treatment.

“There is a shift in research looking at a patient-centric approach and one in which patients are partners and collaborators in research whose participation is core to the success of any research study. It’s a privilege to be asked to help Jodie and her group with this study,” says Sabrina Ramkellawan, Founder of the Canadian Institute for Medical Advancement.

To increase the chances of success with this study, a call for Sponsors, Licensed Producers, and Physicians who understand how life-changing this evidence could be for migraine sufferers is being sent out. Study launch is planned for early 2018, and the hope is to have a number of collaborators in this important study.

Additionally, the organization is also looking for interested potential participants. If you suffer from migraines with MOH, and would like to be a part of migraine history, please connect with Jodie Epstein! jodie@migrainebuds.com https://www.facebook.com/groups/migrainebuds

For media inquiries and/or research partnerships contact Sabrina Ramkellawan at 416-543-5041 or sabrina@cifma.ca. Website: www.cifma.ca

Source: Canadian Institute for Medical Advancement

[ad_2]

Source link

November 10, 2017